STAB (Statera Biopharma) NASDAQ +200.00% pre-market 09 Jan 2026: monitor catalysts
STAB stock is the pre-market top gainer after a 200.00% move, trading on the NASDAQ in the United States ahead of the session on 09 Jan 2026. Statera Biopharma, Inc. (STAB) shows a traded volume near 700.00 and a tiny market cap of 7142.00 USD, with the price at roughly 3.00e-04 USD. The surge follows renewed attention to SEC filings and recent coverage; we break down drivers, financials, technicals and a model forecast from Meyka AI to frame the risk-reward for investors.
Pre-market price action and immediate drivers for STAB stock
STAB stock opened the pre-market session with a sharp move from the prior close of 0.0001 USD to approximately 3.00e-04 USD, a 200.00% change on light volume. One clear trigger is renewed investor attention to recent SEC filings and coverage in market data services. We found mentions of the company in Barron’s and a fresh 10-K listing on MarketBeat that coincided with the move source source.
Company snapshot and key financials for STAB stock
Statera Biopharma, Inc. (STAB) is a US biotechnology company listed on NASDAQ developing immunotherapies for autoimmune disease, hematology and oncology. The company reports EPS of -2.36, shares outstanding of 71416038.00, and a market cap of 7142.00 USD. Cash per share is 0.056375, and the current ratio is 0.37, which signals tight short-term liquidity. These figures help explain why small news items can move the microcap price materially.
Technical picture and trading metrics for STAB stock
The technicals show thin trading history and a low average volume of 18448.00 versus today’s 700.00 share print, producing high volatility. Momentum indicators are mixed: RSI near 45.69 suggests neutral momentum, while ADX at 82.07 signals a strong directional move. Average price levels (50-day ~ 0.000144 USD, 200-day ~ 0.000122 USD) highlight the stock’s long downtrend and extremely low absolute price. For traders, low liquidity and wide bid-ask spreads are the primary execution risks.
Valuation, ratios and analyst context for STAB stock
Standard valuation metrics are limited: price-to-earnings is not meaningful with negative earnings and the company shows price-to-book near -0.00 given negative equity metrics. Enterprise value to EBITDA appears distorted because of near-zero market cap versus recorded enterprise value. Analysts and market-data services list filings and research notes, but no consensus price target exists. Investors should weigh biotech sector dynamics alongside company-specific pipeline milestones when assessing valuation.
Meyka AI rates STAB with a score out of 100 and model forecast
Meyka AI rates STAB with a score out of 100: 64.13 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects a yearly price target of 0.04309 USD. Compared with the current price of 3.00e-04 USD, that implies an upside of approximately 142,630.63%. Forecasts are model-based projections and not guarantees. This evaluation highlights the speculative nature of STAB stock as a microcap biotech with binary pipeline risk.
Catalysts, risks and how to position on STAB stock
Near-term catalysts include regulatory updates, clinical data readouts for STAT-series programs, and SEC disclosures. Key risks are severe: tiny market cap, thin liquidity, negative operating cash flow per share of -0.80, and a high enterprise value relative to market cap, which can indicate outstanding liabilities or distortions. If you trade STAB stock, size positions small, use limit orders and expect wide spreads. For longer-term investors, focus on clinical milestones and financing plans that address the company’s working capital constraints. For a Meyka AI market page on STAB, see our stock hub for live metrics and alerts: Meyka STAB page.
Final Thoughts
STAB stock is a high-volatility microcap biotech that topped pre-market gainers on 09 Jan 2026 with a 200.00% jump. The move reflects low float, thin volume and renewed attention to recent filings and coverage. Fundamental metrics show negative EPS of -2.36, constrained liquidity (current ratio 0.37) and limited revenue history, so price moves are driven more by sentiment and milestone risk than by stable cash flows. Meyka AI’s model projects a yearly price near 0.04309 USD, implying 142,630.63% upside from the current price of 3.00e-04 USD, but this is a model projection and not a guarantee. Given the firm’s biotech pipeline, active traders may find short-term opportunity, while longer-term investors should require clearer clinical or financing catalysts before increasing exposure. Use tight risk controls and treat STAB stock as speculative rather than core portfolio exposure.
FAQs
Why did STAB stock surge pre-market today?
The pre-market surge ties to renewed attention on SEC filings and market-data coverage, combined with thin liquidity and low float. Small trades can move price sharply in microcap stocks like Statera Biopharma.
What is Meyka AI’s grade and forecast for STAB stock?
Meyka AI rates STAB with a score out of 100: 64.13 (Grade B, Suggestion: HOLD). The model projects a yearly price near 0.04309 USD; forecasts are projections and not guarantees.
What are the main risks when trading STAB stock?
Main risks include extreme volatility, thin volume, negative operating cash flow per share of -0.80, a low current ratio of 0.37, and binary clinical or financing outcomes that can wipe value quickly.
Does Statera Biopharma pay dividends or have positive earnings?
No. Statera Biopharma reports negative EPS (-2.36) and no dividend history. The company is clinical-stage and prioritizes R&D financing over payouts.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
